Novavax price target raised to $10 from $2.25 at B. Riley FBR B. Riley FBR analyst George Zavoico raised Novavax's price target to $10 from $2.25 and reiterated a Buy rating after the company provided further details about the FDA's informational analysis of Prepare, an ongoing Phase III trial of an RSV F vaccine for maternal immunization to protect newborn infants.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.